BioCryst Pharmaceuticals BCRX Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's preferred stock, par or stated value per share?
- BioCryst Pharmaceuticals (BCRX) reported preferred stock, par or stated value per share of $0.01 in Q1 2026.
- How has BioCryst Pharmaceuticals's preferred stock, par or stated value per share changed year-over-year?
- BioCryst Pharmaceuticals's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
- What is the long-term trend for BioCryst Pharmaceuticals's preferred stock, par or stated value per share?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.